)
Visual
test
Medmix
Medmix (MEDX) investor relations material
Medmix H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary23 Jul, 2025
Executive summary
Profitability and gross profit rose above guidance despite a 6.5% year-over-year revenue decline to CHF 225.4 million, driven by cost savings and efficiency programs.
CHF 8.5 million in H1 2025 cost savings realized, with CHF 15 million secured toward a CHF 30 million two-year target and 70 initiatives underway.
Strategic focus on reallocating resources, reducing costs, and strengthening management to support future growth.
Recognized as one of only nine Swiss companies to achieve an "A" score in the CDP rating.
Financial highlights
Revenues declined 6.5% year-over-year to CHF 225.4 million (–4.6% organic), with FX effects of –2%.
Adjusted EBITDA margin improved to 19.9% (+80bps), above the 18–19% full-year guidance.
EBIT rose 22.2% year-on-year to CHF 15.7 million, with EBIT margin up 170 basis points to 7%.
Free cash flow increased 50.9% year-over-year to CHF 11.4 million; operating net cash flow slightly decreased due to inventory build-up.
Gross profit reached CHF 82.5 million (+2.4% year-over-year); gross margin 36.6% (+320bps).
Outlook and guidance
Full-year 2025 revenue expected to decline at a rate similar to H1 on an FX-adjusted basis.
Adjusted EBITDA margin guidance for 2025 remains at 18–19%; midterm guidance targets >4% CAGR in revenues and >20% EBITDA margin.
Cost-out program targets CHF 30 million over two years, with CHF 17–20 million expected in 2025.
Price increases from July 2025 to offset most of the U.S. tariff impact, with some lag.
Effectiveness of tariff price increases for 2025
Reconcile secured vs. realized savings for 2025
Expected 2026 revenue impact from new innovations
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- MAERSK
Strong FY25 results with robust cash returns, but FY26 outlook cautious amid market headwinds. - VATN
Record profit, higher dividend, CET1 at 17.2%, and CHF 75m share buyback announced. - MATAS
Record Q3 revenue growth led by Matas, but KICKS declined as consumers traded down. - CZWI
Q2 2025 net income was $3.3M, with margin gains and a 5% buyback authorized. - MILDEF
Record-breaking growth and profitability in 2025, fueled by acquisitions and strong order intake. - MYCR
Q4 sales down 2%, order intake down 19%, but record full-year sales and four acquisitions. - VF
Underlying EBIT up 81% to SEK 30.9 bn; profit down 41% amid divestments and major investments. - ADDT
Earnings and margins rose, acquisitions accelerated, and outlook remains positive. - NCC
Record profits in core segments, major impairment, dividend maintained, outlook positive. - 7004
Order intake and sales rose, but losses and technical issues led to lower profit forecasts.
Next Medmix earnings date
H2 202525 Feb, 2026
Medmix
Next Medmix earnings date
H2 202525 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Medmix AG is a Swiss company specializing in high-precision delivery devices for a variety of sectors, including healthcare, consumer, and industrial applications. The company designs and manufactures mixing, dosing, and application systems, with a product portfolio that includes medical injectors, dental applicators, and industrial mixing solutions. Medmix serves industries requiring precise application and delivery technologies, providing products that meet stringent performance and quality standards. The company is headquartered in Zug, Switzerland, and its shares are listed on the SIX Swiss Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage